GlobeImmune lowers IPO per-share price
Last Updated: 18:37 July 1, 2014
The Louisville-based company plans to raise $15 million by offering 1.5 million shares at $10 per share.
The company had initially filed to offer 2.2 million shares at a range of $15 to $17 but dropped the shares offered to 1.6 million in late May. At the revised price and share count, GlobeImmune would raise 57 percent less than originally planned.
GlobeImmune, which was founded in 1995 and booked $22 million in collaboration and milestone revenue for the 12 months ended March 31, plans to list on the Nasdaq under the symbol GBIM. Aegis Capital is the sole book runner on the deal. It is expected to price during the week of June 30.
Editor's note: An earlier version of this story based information provided by Nasdaq.com stated the IPO would be 1 million shares at a price of $15 per share.
More breaking news...
CEOs: Health care administrative costs still rising
Lacy replaces Kam Mofid, who left the company to pursue other interests, according to a
Brewery takes space in former Butterball building
New Belgium hosting roundtable on EPA water rule